Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 35
Filter
Add more filters










Publication year range
1.
Insect Mol Biol ; 22(2): 211-32, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23398403

ABSTRACT

As important vectors of human disease, phlebotomine sand flies are of global significance to human health, transmitting several emerging and re-emerging infectious diseases. The most devastating of the sand fly transmitted infections are the leishmaniases, causing significant mortality and morbidity in both the Old and New World. Here we present the first global transcriptome analysis of the Old World vector of cutaneous leishmaniasis, Phlebotomus papatasi (Scopoli) and compare this transcriptome to that of the New World vector of visceral leishmaniasis, Lutzomyia longipalpis. A normalized cDNA library was constructed using pooled mRNA from Phlebotomus papatasi larvae, pupae, adult males and females fed sugar, blood, or blood infected with Leishmania major. A total of 47 615 generated sequences was cleaned and assembled into 17 120 unique transcripts. Of the assembled sequences, 50% (8837 sequences) were classified using Gene Ontology (GO) terms. This collection of transcripts is comprehensive, as demonstrated by the high number of different GO categories. An in-depth analysis revealed 245 sequences with putative homology to proteins involved in blood and sugar digestion, immune response and peritrophic matrix formation. Twelve of the novel genes, including one trypsin, two peptidoglycan recognition proteins (PGRP) and nine chymotrypsins, have a higher expression level during larval stages. Two novel chymotrypsins and one novel PGRP are abundantly expressed upon blood feeding. This study will greatly improve the available genomic resources for P. papatasi and will provide essential information for annotation of the full genome.


Subject(s)
Gene Expression Profiling , Insect Proteins/genetics , Phlebotomus/genetics , Amino Acid Sequence , Animals , Blood/parasitology , Chymotrypsin/genetics , Chymotrypsin/metabolism , Expressed Sequence Tags , Female , Gene Library , Insect Vectors/genetics , Leishmania major , Male , Molecular Sequence Data , Phylogeny , Polymorphism, Single Nucleotide , Psychodidae/genetics , Sequence Homology, Amino Acid , Trypsin/genetics , Trypsin/metabolism
2.
Science ; 330(6003): 512-4, 2010 Oct 22.
Article in English | MEDLINE | ID: mdl-20966253

ABSTRACT

The Afrotropical mosquito Anopheles gambiae sensu stricto, a major vector of malaria, is currently undergoing speciation into the M and S molecular forms. These forms have diverged in larval ecology and reproductive behavior through unknown genetic mechanisms, despite considerable levels of hybridization. Previous genome-wide scans using gene-based microarrays uncovered divergence between M and S that was largely confined to gene-poor pericentromeric regions, prompting a speciation-with-ongoing-gene-flow model that implicated only about 3% of the genome near centromeres in the speciation process. Here, based on the complete M and S genome sequences, we report widespread and heterogeneous genomic divergence inconsistent with appreciable levels of interform gene flow, suggesting a more advanced speciation process and greater challenges to identify genes critical to initiating that process.


Subject(s)
Anopheles/genetics , Genetic Speciation , Genome, Insect , Animals , Anopheles/classification , Evolution, Molecular , Female , Gene Flow , Male , Models, Genetic , Polymorphism, Single Nucleotide
3.
J Allergy Clin Immunol ; 108(2): 250-7, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11496242

ABSTRACT

BACKGROUND: Allergic respiratory diseases are characterized by large numbers of eosinophils and their reactive products in airways and blood; these are believed to be involved in progressive airway damage and remodeling. IL-5 is the principal cytokine for eosinophil maturation, differentiation, and survival. Mepolizumab (SB-240563), a humanized monoclonal antibody (mAb) specific for human IL-5, is currently in clinical trials for treatment of asthma. OBJECTIVE: The purpose of this study was to characterize the pharmacologic activity and long-term safety profile of an anti--human IL-5 mAb to support clinical trials in asthmatic patients. METHODS: Naive and Ascaris suum -sensitive cynomolgus monkeys received various dose levels of mepolizumab and were monitored for acute and chronic pharmacologic and toxic responses. RESULTS: To support preclinical safety assessment, cynomolgus monkey IL-5 was cloned, expressed, and characterized. Although monkey IL-5 differs from human IL-5 by 2 amino acids (Ala27Gly and Asn40His), mepolizumab has comparable inhibitory activity against both monkey IL-5 and human IL-5. In A suum--sensitive monkeys, single doses of mepolizumab significantly reduced blood eosinophilia, eosinophil migration into lung airways, and levels of RANTES and IL-6 in lungs for 6 weeks. However, mepolizumab did not affect acute bronchoconstrictive responses to inhaled A suum. In an IL-2--induced eosinophilia model (up to 50% blood eosinophilia), 0.5 mg/kg mepolizumab blocked eosinophilia by >80%. Single-dose and chronic (6 monthly doses) intravenous and subcutaneous toxicity studies in naive monkeys found no target organ toxicity or immunotoxicity up to 300 mg/kg. Monkeys did not generate anti-human IgG antibodies. Monthly mepolizumab doses greater than 5 mg/kg caused an 80% to 100% decrease in blood and bronchoalveolar lavage eosinophils lasting 2 months after dosing, and there was no effect on eosinophil precursors in bone marrow after 6 months of treatment. Eosinophil decreases correlated with mepolizumab plasma concentrations (half-life = 13 days). CONCLUSION: These studies demonstrate that chronic antagonism of IL-5 by mepolizumab in monkeys is safe and has the potential, through long-term reductions in circulating and tissue-resident eosinophils, to be beneficial therapy for chronic inflammatory respiratory diseases.


Subject(s)
Anti-Asthmatic Agents/therapeutic use , Antibodies, Monoclonal/therapeutic use , Asthma/therapy , Eosinophils/drug effects , Interleukin-5/immunology , Animals , Anti-Asthmatic Agents/pharmacology , Anti-Asthmatic Agents/toxicity , Antibodies, Monoclonal/pharmacology , Antibodies, Monoclonal/toxicity , Antibodies, Monoclonal, Humanized , Cell Count , Cloning, Molecular , Drug Evaluation, Preclinical , Eosinophils/cytology , Immunotherapy , Interleukin-5/antagonists & inhibitors , Interleukin-5/genetics , Macaca fascicularis , Male , Safety , Species Specificity
4.
Protein Expr Purif ; 22(2): 330-6, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11437610

ABSTRACT

CD23, a 45-kDa type II membrane glycoprotein present on B cells, monocytes, and other human immune cells, is a low-affinity receptor for IgE. The extracellular region of the membrane-bound human CD23 is processed into at least four soluble (s) CD23 forms, with apparent molecular masses of 37, 33, 29, and 25 kDa. High levels of sCD23 are found in patients with allergy, certain autoimmune diseases, or chronic lymphocytic leukemia. Therefore, inhibition of the processing of membrane-bound CD23 to control the cytokine-like effects of sCD23 offers a novel therapeutic opportunity. While the 37-, 29-, and 25-kDa forms of sCD23 have been expressed previously as recombinant proteins, the 33-kDa form has not been purified and characterized. To further investigate the multiple roles of sCD23 fragments and to devise assays to identify potent small-molecule inhibitors of CD23 processing, we have produced the 33-kDa form of sCD23 using Chinese hamster ovary (CHO) and Drosophila S2 cells. The CHO-expressed 33-kDa protein was found to undergo proteolytic degradation during cell growth and during storage of purified protein, resulting in accumulation of a 25-kDa form. The Drosophila system expressed the 33-kDa sCD23 in a stable form that was purified and demonstrated to be more active than the CHO-derived 25-kDa form in a monocyte TNFalpha release assay.


Subject(s)
Drosophila/genetics , Receptors, IgE/genetics , Receptors, IgE/isolation & purification , Amino Acid Sequence , Animals , CHO Cells , Cell Line , Cloning, Molecular , Cricetinae , Drosophila/cytology , Genetic Vectors , Humans , Molecular Sequence Data , Molecular Weight , Monocytes/metabolism , Receptors, IgE/biosynthesis , Receptors, IgE/metabolism , Solubility , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization , Tumor Necrosis Factor-alpha/metabolism
5.
Diabetologia ; 43(6): 809-13, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10907127

ABSTRACT

AIM/HYPOTHESIS: Electroacupuncture has been shown to induce a short-term hypoglycaemic effect in streptozotocin diabetic rats. We designed an experiment to investigate the effect of electroacupuncture in Psammomys obesus, a model of insulin resistance and non-insulin-dependent diabetes mellitus. METHODS: We divided 29 diabetic Psammomys randomly into three groups: abdominal electroacupuncture (real, n = 11), back electroacupuncture (placebo, n = 9) and control (anaesthesia, n = 9). Electroacupuncture was carried out on days 1, 3 and 5 of the experiment. During the first week of the experiment, blood glucose was tested three times on treatment days and once on the following days. Over the next 2 weeks, blood glucose was tested every other day. Animals were weighed at the same time of blood sampling. After 3 weeks, at the end of the experiment, blood was drawn for measurement of insulin, fructosamine, cholesterol and triglycerides. RESULTS: At day 5 (end of intervention), blood glucose (as per cent of primary concentrations, means +/- SE) was 57 +/- 10, 93 +/- 13 and 89 +/- 11 for the real, placebo and control groups respectively (p = 0.02). At day 8, blood glucose 68 +/- 14, 86 +/- 16 and 97 +/- 9 for the real, placebo and control groups respectively (p = 0.04). At day 22, blood glucose was 79 +/- 11, 85 +/- 15 and 131 +/- 2 for the real, placebo and control groups (p = 0.04). Comparison of the decline in blood glucose, throughout the 3 weeks, between the real and placebo groups by ANOVA was highly significant (p < 0.0001), the difference between the placebo and control groups at the same time was not significant (p > 0.05). Animal weight gain, serum insulin, fructosamine, cholesterol and triglycerides were not significantly different between real and placebo groups. CONCLUSION/INTERPRETATION: Electroacupuncture at special abdominal acupoints induces a sustained hypoglycaemic effect in diabetic Psammomys compared with electroacupuncture at non-specific points, without weight loss. No hypoinsulinaemic effect was shown in the real and placebo groups.


Subject(s)
Diabetes Mellitus, Type 2/therapy , Electroacupuncture , Hypoglycemia/etiology , Analysis of Variance , Animals , Blood Glucose/metabolism , Cholesterol/blood , Diabetes Mellitus, Type 2/blood , Disease Models, Animal , Fructosamine/blood , Gerbillinae , Insulin/blood , Insulin Resistance , Male , Rats , Time Factors , Triglycerides/blood
6.
Clin Exp Allergy ; 30(5): 719-27, 2000 May.
Article in English | MEDLINE | ID: mdl-10792365

ABSTRACT

BACKGROUND: CD23, the low affinity serum immunoglobulin E (IgE) receptor, is upregulated on B cells following interleukin (IL)-4 stimulation and is concomitantly cleaved to generate soluble CD23 (sCD23) fragments with cytokine-like activity. OBJECTIVE: Compounds that selectively inhibit the proteolytic release of CD23 to generate sCD23 were assessed for their ability to inhibit IgE production in order to evaluate the contribution of sCD23 in the production of human IgE as well as the ability of such compounds to block IgE production. METHODS: IgE production was measured in IL-4-stimulated human peripheral blood lymphocytes (PBL) and PBL-reconstituted SCID mice in the presence of a broad-spectrum matrix metalloprotease (MMP) inhibitor, a compound selective for inhibition of CD23 processing over MMPs and an anti-CD23 mAb, MHM6. RESULTS: The two compounds were equipotent in inhibiting IgE production without inhibition of IgG production by IL-4/anti-CD40-stimulated PBL. Soluble CD23 release was also shown to precede IgE accumulation in the cell-free medium. Addition of compound at later times other than day 0 in the 14 day assay resulted in progressively less inhibition of both IgE and sCD23, and exactly paralleled the effect of an anti-CD23 mAb, MHM6 on IgE levels. Both compounds also inhibited the release of CD23 from human RPMI 8866 cells adoptively transferred i. p. to mice. Doses required for inhibition of CD23 correlated well with the doses required for inhibition of IgE production in IL-4-challenged hu-PBL-SCID mice. IgE was selectively inhibited over total IgG in the SCID mice as well. CONCLUSIONS: Inhibition of CD23 processing alone is sufficient to inhibit IL-4-stimulated IgE production both in vitro and in vivo.


Subject(s)
Enzyme Inhibitors/pharmacology , Immunoglobulin E/biosynthesis , Immunosuppressive Agents/pharmacology , Interleukin-4/antagonists & inhibitors , Interleukin-4/physiology , Lymphocytes/metabolism , Protein Processing, Post-Translational/immunology , Receptors, IgE/antagonists & inhibitors , Animals , Chimera , Humans , Lymphocyte Transfusion , Lymphocytes/drug effects , Lymphocytes/immunology , Matrix Metalloproteinase Inhibitors , Mice , Mice, SCID , Peptide Fragments/antagonists & inhibitors , Peptide Fragments/metabolism , Protein Processing, Post-Translational/drug effects , Receptors, IgE/metabolism , Solubility
7.
Cell Immunol ; 193(2): 226-35, 1999 May 01.
Article in English | MEDLINE | ID: mdl-10222066

ABSTRACT

Two human CC chemokines, SLC/6Ckine/Exodus2/TCA4 and CKbeta-11/MIP-3beta/ELC, are previously reported as efficacious chemoattractants for T- and B-cells and dendritic cells. SLC and CKbeta-11 share only 32% amino acid identity, but are ligands for the same chemokine receptor, CCR7. In this study, we examined chemotactic activity of SLC and CKbeta-11 for NK cells and lymphoid progenitors in bone marrow and thymus. It was found that these two CCR7 ligands are chemoattractants for neonatal cord blood and adult peripheral blood NK cells and cell lines. SLC and CKbeta-11 preferentially attract the CD56(+)CD16(-) NK cell subset over CD56(+)CD16(+) NK cells. SLC and CKbeta-11 also demonstrate selective chemotactic activity on late stage CD34(-)CD19(+)IgM- B-cell progenitors and CD4(+) and CD8(+) single-positive thymocytes, but not early stage progenitors. It was noted that SLC is an efficient desensitizer of CKbeta-11-dependent NK cell chemotaxis, while CKbeta-11 is a weak desensitizer of SLC-dependent chemotaxis. Taken together, these results suggest that SLC and CKbeta-11 have the potential to control trafficking of NK cell subsets and late stage lymphoid progenitors in bone marrow and thymus.


Subject(s)
Chemokines, CC/metabolism , Chemotaxis, Leukocyte , Hematopoietic Stem Cells/physiology , Killer Cells, Natural/physiology , Receptors, Chemokine/metabolism , CD56 Antigen/isolation & purification , Cell Polarity , Chemokine CCL19 , Chemokine CCL21 , Cytotoxicity, Immunologic , Exocytosis , Humans , Ligands , Lymphocyte Subsets/physiology , Protein Binding , Receptors, CCR7 , Receptors, IgG/isolation & purification , Thymus Gland/cytology
8.
J Immunol ; 161(11): 6273-9, 1998 Dec 01.
Article in English | MEDLINE | ID: mdl-9834116

ABSTRACT

A new CC chemokine, designated CKbeta-8 or myeloid progenitor inhibitor factor-1, was recently identified in a large scale sequencing effort and was cloned from a human aortic endothelial library. CKbeta-8 cDNA encodes a signal sequence of 21 amino acids, followed by a 99-amino acid predicted mature form. CKbeta-8 was expressed and purified from a baculovirus insect cell expression system, which resulted in the identification of different N-terminal variants of the secreted chemokine. The three major forms (containing amino acids 1-99, 24-99, and 25-99 of the secreted chemokine) showed a large variation in potency. CKbeta-8 activated both monocytes and eosinophils to mobilize intracellular calcium; however, the shortest form of CKbeta-8 (25-99) was >2 orders of magnitude more potent than the longest form. Cross-desensitization experiments in both monocytes and eosinophils suggested that the CCR1 receptor was probably the predominant receptor that mediates this chemokine's physiologic response. However, incomplete desensitization was encountered in both cell systems, suggesting involvement of an additional receptor(s). Interestingly, the short form of CKbeta-8 was the most potent chemotactic chemokine that we have ever evaluated in the monocyte system (EC50 = 54 pM). However, in contrast to its action on monocytes, CKbeta-8 was a very poor chemotactic factor for eosinophils.


Subject(s)
Chemokines, CC/chemistry , Chemokines, CC/isolation & purification , Amino Acid Sequence , Calcium/metabolism , Chemokines, CC/genetics , Chemokines, CC/metabolism , Chemotactic Factors, Eosinophil/physiology , Chemotaxis, Leukocyte/drug effects , Eosinophils/immunology , Eosinophils/metabolism , Humans , Molecular Sequence Data , Monocyte Chemoattractant Proteins/physiology , Monocytes/immunology , Monocytes/metabolism , Protein Isoforms/chemistry , Protein Isoforms/immunology , Protein Isoforms/isolation & purification , Recombinant Proteins/biosynthesis , Recombinant Proteins/chemistry , Recombinant Proteins/pharmacology
9.
Anal Chem ; 70(22): 4761-70, 1998 Nov 15.
Article in English | MEDLINE | ID: mdl-9844572

ABSTRACT

A solution-based microscale approach for determination of high-affinity noncovalent complexes from mixtures of compounds is presented, based on capillary isoelectric focusing coupled on-line with electrospray ionization ion trap mass spectrometry. The studies are performed using the src homology 2 domain and tyrosine-phosphorylated peptide ligands as a model system. Tight complexes are formed in solution, preconcentrated up to 2 orders of magnitude and separated on the basis of their isoelectric points. The complexes are then dissociated in the mass spectrometer and the freed ligands identified. Picomole or less amounts of protein reagent are consumed per experiment. Structural information for the ligands involved in tight complex formation may be obtained using the MSn capabilities of the ion trap. The methodology can potentially be used to screen rapidly combinatorial mixtures of compounds for high-affinity ligands.


Subject(s)
Peptides/analysis , Phosphotyrosine/analysis , Electrophoresis, Capillary , Isoelectric Focusing , Mass Spectrometry , Spectrophotometry, Ultraviolet
10.
J Biol Chem ; 273(23): 14363-7, 1998 Jun 05.
Article in English | MEDLINE | ID: mdl-9603945

ABSTRACT

TRAIL is a tumor necrosis factor-related ligand that induces apoptosis upon binding to its death domain-containing receptors, DR4 and DR5. Two additional TRAIL receptors, TRID/DcR1 and DcR2, lack functional death domains and function as decoy receptors for TRAIL. We have identified a fifth TRAIL receptor, namely osteoprotegerin (OPG), a secreted tumor necrosis factor receptor homologue that inhibits osteoclastogenesis and increases bone density in vivo. OPG-Fc binds TRAIL with an affinity of 3.0 nM, which is slightly weaker than the interaction of TRID-Fc or DR5-Fc with TRAIL. OPG inhibits TRAIL-induced apoptosis of Jurkat cells. Conversely, TRAIL blocks the anti-osteoclastogenic activity of OPG. These data suggest potential cross-regulatory mechanisms by OPG and TRAIL.


Subject(s)
Apoptosis/physiology , Glycoproteins/physiology , Membrane Glycoproteins/physiology , Receptors, Cytoplasmic and Nuclear , Receptors, Tumor Necrosis Factor/physiology , Tumor Necrosis Factor-alpha/physiology , Animals , Apoptosis Regulatory Proteins , Binding, Competitive , GPI-Linked Proteins , Humans , Immunoglobulin Fc Fragments/genetics , Immunohistochemistry , Jurkat Cells , Ligands , Mice , Microscopy, Fluorescence , Oligopeptides , Osteoclasts/cytology , Osteoprotegerin , Peptides/immunology , Protein Binding/physiology , Receptors, TNF-Related Apoptosis-Inducing Ligand , Receptors, Tumor Necrosis Factor/classification , Receptors, Tumor Necrosis Factor/metabolism , Receptors, Tumor Necrosis Factor, Member 10c , Receptors, Tumor Necrosis Factor, Member 25 , Recombinant Fusion Proteins/metabolism , TNF-Related Apoptosis-Inducing Ligand , Tumor Necrosis Factor Decoy Receptors
11.
J Leukoc Biol ; 62(5): 667-75, 1997 Nov.
Article in English | MEDLINE | ID: mdl-9365122

ABSTRACT

Eotaxin has been found to bind exclusively to a single chemokine receptor, CCR3. Using expression sequence tag screening of an activated monocyte library, a second chemokine has been identified; it was expressed and purified from a Drosophila cell culture system and appears to only activate CCR3. Eotaxin-2, MPIF-2, or CKbeta-6, is a human CC chemokine with low amino acid sequence identity to other chemokines. Eotaxin-2 promotes chemotaxis and Ca2+ mobilization in human eosinophils but not in neutrophils or monocytes. Cross-desensitization calcium mobilization experiments using purified eosinophils indicate that eotaxin and MCP-4, but not RANTES, MIP-1alpha, or MCP-3, can completely cross-desensitize the calcium response to eotaxin-2 on these cells, indicating that eotaxin-2 shares the same receptor used by eotaxin and MCP-4. Eotaxin-2 was the most potent eosinophil chemoattractant of all the chemokines tested. Eotaxin-2 also displaced 125I-eotaxin bound to the cloned CCR3 stably expressed in CHO cells (CHO-CCR3) and to freshly isolated human eosinophils with affinities similar to eotaxin and MCP-4. 125I-Eotaxin-2 binds with high affinity to eosinophils and both eotaxin and cold eotaxin-2 displace the ligand with equal affinity. Eotaxin and eotaxin-2 promote a Ca2+ transient in RBL-2H3 cells stably transfected with CCR3 (RBL-2H3-CCR3) and both ligands cross-desensitized the response of the other but not the response to LTD4. The data indicate that eotaxin-2 is a potent eosinophil chemotactic chemokine exerting its activity solely through the CCR3 receptor.


Subject(s)
Chemokines, CC , Chemokines/physiology , Eosinophils/physiology , Receptors, Chemokine/metabolism , Amino Acid Sequence , Animals , Binding, Competitive , CHO Cells/metabolism , Calcium/metabolism , Cell Movement/physiology , Chemokine CCL11 , Chemokine CCL24 , Chemokine CCL8 , Chemokines/genetics , Chemokines/isolation & purification , Cloning, Molecular , Cricetinae , Cytokines/genetics , DNA, Complementary/genetics , Eosinophils/drug effects , Eosinophils/metabolism , Humans , Molecular Sequence Data , Monocyte Chemoattractant Proteins/genetics , Rats , Receptors, CCR3 , Receptors, Chemokine/physiology
12.
J Biol Chem ; 272(26): 16404-13, 1997 Jun 27.
Article in English | MEDLINE | ID: mdl-9195948

ABSTRACT

Here we describe the characterization of a novel human CC chemokine, tentatively named monocyte chemotactic protein (MCP-4). This chemokine was detected by random sequencing of expressed sequence tags in cDNA libraries. The full-length cDNA revealed an open reading frame for a 98-amino acid residue protein, and a sequence alignment with known CC chemokines showed high levels of similarity (59-62%) with MCP-1, MCP-3, and eotaxin. MCP-4 cDNA was cloned into Drosophila S2 cells, and the mature protein (residues 24-98) was purified from the conditioned medium. Recombinant MCP-4 induced a potent chemotactic response (EC50 = 2.88 +/- 0.15 nM) and a transient rise in cytosolic calcium concentration in fresh human peripheral blood monocytes but not in neutrophils. Binding studies in monocytes showed that MCP-4 and MCP-3 were very potent in displacing high affinity binding of 125I-MCP-1 (IC50 for MCP-4, MCP-3, and unlabeled MCP-1 of 2.1 +/- 1.4, 0.85-1.6, and 0.7 +/- 0.2 nM respectively), suggesting that all three chemokines interact with the CC chemokine receptor-2 (MCP-1 receptor). This was confirmed in binding studies with Chinese hamster ovary cells, stably transfected with the CC chemokine 2B receptor. Northern blot analysis in extracts of normal human tissues showed expression of mRNA for MCP-4 in small intestine, thymus, and colon, but the level of protein expression was too low to be detected in Western blot analysis. However, expression of MCP-4 protein was demonstrated by immunohistochemistry in human atherosclerotic lesion and found to be associated with endothelial cells and macrophages.


Subject(s)
Monocyte Chemoattractant Proteins/metabolism , Receptors, Chemokine , Receptors, Cytokine/metabolism , Amino Acid Sequence , Animals , Arteriosclerosis/metabolism , Binding, Competitive , Blotting, Western , CHO Cells , Calcium/metabolism , Cloning, Molecular , Cricetinae , Humans , Molecular Sequence Data , Monocyte Chemoattractant Proteins/analysis , Monocyte Chemoattractant Proteins/pharmacology , RNA, Messenger/analysis , Receptors, CCR2 , Recombinant Proteins/biosynthesis
13.
Calcif Tissue Int ; 60(4): 380-6, 1997 Apr.
Article in English | MEDLINE | ID: mdl-9075637

ABSTRACT

Studies to assess osteopontin (OPN) localization in adult human bone using immunochemical techniques produce conflicting results due to variations in tissue processing or antibody immunoreactivity. The present study was designed to resolve these discrepancies using well-characterized antibodies and improved antigen detection. An anti-osteopontin (alpha-OPN) antiserum was developed that recognizes various soluble molecular weight forms of human OPN, including monomeric, cleaved, and dimerized products. An affinity column of full length recombinant human OPN (rOPN) coupled to support was used to purify alpha-OPN antibodies. Western analysis showed that the affinity-purified antibodies recognized numerous molecular weight forms of OPN. These antibodies were used to study the distribution of OPN in adult human bone using immunohistochemical techniques combined with an antigen retrieval protocol utilizing a newly developed antigen retrieval solution, Retriev-Alltrade mark (Bronco Technologies Inc, Pasadena, TX). Immunolocalization of OPN in archival bone specimens prior to antigen retrieval produced no demonstrable immunostaining even at high concentrations of alpha-OPN. Use of the antigen retrieval protocol restored OPN immunoreactivity, with strong staining apparent in cement lines, osteoblasts, osteocytes, canaliculi, osteoid, and bone matrix. We conclude that antigen retrieval restores immunochemical recognition of OPN in archival specimens containing bone without increasing nonspecific binding.


Subject(s)
Antibodies/immunology , Bone and Bones/chemistry , Sialoglycoproteins/analysis , Adult , Animals , Antibody Specificity , Blotting, Western , Female , Goats/immunology , Humans , Ilium/chemistry , Immune Sera , Immunoenzyme Techniques , Kidney Tubules/chemistry , Male , Milk Proteins/analysis , Milk, Human/chemistry , Molecular Weight , Organ Specificity , Osteopontin , Paraffin Embedding , Prostate/chemistry , Recombinant Fusion Proteins/analysis , Sensitivity and Specificity , Sialoglycoproteins/chemistry , Sialoglycoproteins/genetics , Sialoglycoproteins/immunology , Sialoglycoproteins/isolation & purification , Solutions , Specimen Handling , Tissue Fixation
14.
J Bone Miner Res ; 10(11): 1666-80, 1995 Nov.
Article in English | MEDLINE | ID: mdl-8592943

ABSTRACT

Osteopontin is a phosphorylated glycoprotein believed to be secreted by osteoblasts and deposited into the bone matrix to facilitate osteoclasts adhesion or to initiate osteoid mineralization. Previously we have presented contradictory evidence that osteoclasts express osteopontin mRNA in human remodeling bone. The aim of this study was to ascertain whether osteoclasts synthesize and deposit osteopontin in resorption lucunae. We characterized expression of osteopontin mRNA and protein expression in both intramembranous and endochondral ossification, as well as remodeling bone, in the human osteophyte. Osteopontin mRNA was expressed in osteoclast with tartrate-resistant acid phosphatase (TRAP) positivity within resorption lacunae. The osteoclasts and immediate resorption surfaces also expressed osteopontin. However, osteopontin mRNA and protein were weak (transient) or undetectable in osteoblasts at adjacent bone formation sites; no osteopontin expression was observed in the osteoid, although occasional reactivity was observed in osteocytes and the mineral-osteoid interface. In contrast, osteopontin was highly expressed in the osteoblasts and matrix of woven bone during intramembranous and endochondral ossification. The matrix expression correlated with mineralization; however, in some instances osteopontin deposition was observed prior to mineralization. Similarly, osteopontin expression was evident in cartilage matrix, solely at foci of mineralization. Chondroclasts expressed osteopontin mRNA and protein: the surfaces of resorbed calcified cartilage also expressed osteopontin. Abnormal, unmineralized matrices apparently lacked deposited osteopontin, but were nevertheless resorbed by osteoclasts; the osteoclasts and resorbed surfaces expressed no osteopontin protein. That osteoclasts are responsible for the deposition of osteopontin was confirmed in vitro, whereby resorption pits in whale dentine and bovine bone slices, produced by isolated human osteoclasts, contained deposited osteopontin. Osteopontin may facilitate the adhesion (or detachment) of the osteoclast to the bone surface. Alternatively, the possibility that osteopontin may act as a postresorptive signal to recruit osteoblasts, or to polarize and direct the mineralization of the formed osteoid, is discussed.


Subject(s)
Bone Resorption/metabolism , Osteoclasts/metabolism , Sialoglycoproteins/metabolism , Acid Phosphatase/metabolism , Bone Remodeling/physiology , Bone Resorption/pathology , Calcification, Physiologic/physiology , Cartilage/cytology , Cartilage/metabolism , Cell Adhesion/physiology , DNA, Complementary/metabolism , Femur Head/metabolism , Histocytochemistry , Humans , Immunohistochemistry , In Situ Hybridization , Osteoarthritis/pathology , Osteoclasts/cytology , Osteopontin , Promoter Regions, Genetic/genetics , RNA, Messenger/metabolism , Sialoglycoproteins/genetics , Tartrates/pharmacology
15.
J Immunol ; 154(12): 6355-64, 1995 Jun 15.
Article in English | MEDLINE | ID: mdl-7759873

ABSTRACT

Conventional hybridomas and combinatorial Ab libraries were used to develop neutralizing murine mAbs to human IL-5. Mice were immunized with rIL-5. Spleens from two mice were used to generate hybridomas. Spleens from an additional three mice were used to construct a combinatorial library. In both instances, Abs were identified and selected by ELISA using 96-well plates coated with rIL-5. These Abs were tested for the ability to block binding of iodinated rIL-5 to the alpha-chain of the human IL-5 receptor (IL-5R alpha) and to inhibit proliferation of IL-5-dependent cells. By hybridoma technology, 16 mAbs were obtained, 11 of which blocked binding to IL-5R alpha, including three that inhibited proliferation. Quantitative binding assays and sequence analysis revealed that these latter three mAbs were closely related. Combinatorial cloning and selection by phage display was used to isolate 24 bacterial colonies secreting Fabs that bound to 125I-rIL-5 and to rIL-5-coated plates. Sequencing of 10 of the Fabs indicated that four unique Abs were obtained, comprising one predominant VH paired with one of two different VL. The sequence of the Fabs was distinct from the sequences of the neutralizing mAbs. In contrast to the mAbs, none of the Fabs blocked binding of 125I-IL-5 to IL-5R alpha or neutralized the biologic activity of IL-5. The inability to identify neutralizing Fabs was shown not to result from their monovalency, because a Fab derived from one of the neutralizing mAbs, by cloning and expression of its Fd and kappa light chains, retained neutralizing activity. By chain shuffling, pairing of the Fd fragment of the heavy chain of one of the neutralizing mAbs (2B6), with the light chain library derived from the IL-5-immunized mice, neutralizing Fabs were obtained. These Fabs contained light chain sequences closely related to the original light chain of 2B6. Hence, chain shuffling allowed detection of a light chain sequence that was not evident upon two-chain combinatorial selection. The results reveal differences in the Abs obtained from a combinatorial library vs hybridomas and demonstrate how these approaches can be used in concert to select mAbs with neutralizing activity.


Subject(s)
Antibodies, Monoclonal , Interleukin-5/immunology , Amino Acid Sequence , Animals , Antibodies, Monoclonal/genetics , Antibodies, Monoclonal/isolation & purification , Bacteriophage M13/genetics , Base Sequence , Cloning, Molecular , DNA Primers/genetics , DNA, Complementary/genetics , Escherichia coli/genetics , Gene Library , Humans , Hybridomas/immunology , Immunization , Immunoglobulin Fab Fragments/genetics , Immunoglobulin Fab Fragments/isolation & purification , Immunoglobulin Heavy Chains/genetics , Immunoglobulin kappa-Chains/genetics , Mice , Molecular Sequence Data , Neutralization Tests
16.
J Biol Chem ; 270(16): 9459-71, 1995 Apr 21.
Article in English | MEDLINE | ID: mdl-7721873

ABSTRACT

Human interleukin 5 (hIL5) and soluble forms of its receptor alpha subunit were expressed in Drosophila cells and purified to homogeneity, allowing a detailed structural and functional analysis. B cell proliferation confirmed that the hIL5 was biologically active. Deglycosylated hIL5 remained active, while similarly deglycosylated receptor alpha subunit lost activity. The crystal structure of the deglycosylated hIL5 was determined to 2.6-A resolution and found to be similar to that of the protein produced in Escherichia coli. Human IL5 was shown by analytical ultracentrifugation to form a 1:1 complex with the soluble domain of the hIL5 receptor alpha subunit (shIL5R alpha). Additionally, the relative abundance of ligand and receptor in the hIL5.shIL5R alpha complex was determined to be 1:1 by both titration calorimetry and SDS-polyacrylamide gel electrophoresis analysis of dissolved cocrystals of the complex. Titration microcalorimetry yielded equilibrium dissociation constants of 3.1 and 2.0 nM, respectively, for the binding of hIL5 to shIL5R alpha and to a chimeric form of the receptor containing shIL5R alpha fused to the immunoglobulin Fc domain (shIL5R alpha-Fc). Analysis of the binding thermodynamics of IL5 and its soluble receptor indicates that conformational changes are coupled to the binding reaction. Kinetic analysis using surface plasmon resonance yielded data consistent with the Kd values from calorimetry and also with the possibility of conformational isomerization in the interaction of hIL5 with the receptor alpha subunit. Using a radioligand binding assay, the affinity of hIL5 with full-length hIL5R alpha in Drosophila membranes was found to be 6 nM, in accord with the affinities measured for the soluble receptor forms. Hence, most of the binding energy of the alpha receptor is supplied by the soluble domain. Taken with other aspects of hIL5 structure and biological activity, the data obtained allow a prediction for how 1:1 stoichiometry and conformational change can lead to the formation of hIL5.receptor alpha beta complex and signal transduction.


Subject(s)
Interleukin-5/metabolism , Receptors, Interleukin/metabolism , Amino Acid Sequence , Animals , Calorimetry , Crystallization , Drosophila/genetics , Humans , Interleukin-5/chemistry , Molecular Sequence Data , Molecular Weight , Receptors, Interleukin/chemistry , Receptors, Interleukin-5 , Recombinant Proteins/biosynthesis , Recombinant Proteins/chemistry
17.
J Mol Recognit ; 8(1-2): 52-8, 1995.
Article in English | MEDLINE | ID: mdl-7598953

ABSTRACT

The interaction of biotinylated human interleukin 5 ([BT]hIL5) with immobilized receptor was measured with a real-time biosensor, and these results were used as a basis for configuring an ELISA for screening antagonists of hIL5-receptor binding. The recombinant proteins used, hIL5 and shIL5R alpha-Fc (chimeric fusion receptor constructed by linking the soluble component of the hIL5 receptor alpha subunit to the constant domain (Fc) of immunoglobulin G), were produced by the expression of cloned vectors in Drosophila schneider (S2) cells. Initial attempts to develop a screening assay by direct immobilization of soluble IL5 receptor to microtiter plates proved unsatisfactory and led to use of the Fc chimera attached by oriented immobilization via protein A. Hence, shIL5R alpha-Fc was bound to protein A covalently immobilized on a carboxymethyl dextran (CM-5) biosensor chip. Specific binding was demonstrated of [BT]hIL5 to protein A/shIL5R alpha-Fc receptor complex. The binding was high affinity (Kdapp = 6 nM), reversible and saturable. The affinity of [BT]hIL5 was similar to that determined with the biosensor assay for unmodified hIL5. The observed kinetics of the interactions of Fc chimera with protein A (slow dissociation) and of [BT]hIL5 with immobilized Fc chimera (faster dissociation) were favorable for subsequently establishing a microtiter plate based ELISA assay. In the latter, Fc chimera was immobilized to the plate via protein A as in the biosensor experiment. Binding of [BT]hIL5 to immobilized Fc chimera in the ELISA was concentration dependent and was competed by both hIL5 and shIL5R alpha.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Interleukin-5/metabolism , Receptors, Fc/metabolism , Animals , Biosensing Techniques , Biotin , Cloning, Molecular , Drosophila , Enzyme-Linked Immunosorbent Assay/methods , Gene Expression , Humans , Interleukin-5/biosynthesis , Kinetics , Protein Binding , Protein Conformation , Receptors, Fc/biosynthesis , Recombinant Fusion Proteins/biosynthesis , Recombinant Proteins/biosynthesis , Recombinant Proteins/metabolism
18.
J Mol Recognit ; 7(1): 47-55, 1994 Mar.
Article in English | MEDLINE | ID: mdl-7986567

ABSTRACT

A surface plasmon resonance (SPR) biosensor was used to study the interaction of human interleukin-5 (hIL5) with its receptor. IL5 is a major growth factor in the production and activation of eosinophils. The receptor for IL5 is composed of two subunits, alpha and beta. The alpha subunit provides the specificity for IL5 and consists of an extracellular soluble domain, a single transmembrane region and a cytoplasmic tail. We expressed the soluble domain of the human IL5 receptor alpha subunit (shIL5R alpha) and human IL5 (hIL5) in Drosophila. Both hIL5 and shIL5R alpha were immobilized separately through amine groups onto the carboxylated dextran layer of sensor chips of the BIAcore (Pharmacia) SPR biosensor after N-hydroxysuccinimide/carbodiimide activation of the chip surface. Interactions were measured for the complementary macromolecule, either shIL5R alpha or hIL5, in solution. Kinetics of binding of soluble analyte to immobilized ligand were measured and from this the association rate constant, dissociation rate constant and equilibrium dissociation constant (Kd) were derived. With immobilized shIL5R alpha and soluble hIL5, the measured Kd was 2 nM. A similar value was obtained by titration calorimetry. The Kd for Drosophila expressed receptor and IL5 is higher than the values reported for proteins expressed in different systems, likely due to differences in the methods of interaction analysis used or differences in protein glycosylation. Receptor-IL5 binding was relatively pH independent between pH 6.5 and 9.5. Outside this range, the dissociation rate increased with comparatively little increase in association rate.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Biosensing Techniques , Interleukin-5/metabolism , Protein Structure, Tertiary , Receptors, Interleukin/metabolism , Animals , Calorimetry , Drosophila , Humans , Hydrogen-Ion Concentration , Interleukin-5/chemistry , Microchemistry , Protein Binding , Receptors, Interleukin/chemistry , Receptors, Interleukin-5 , Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/metabolism
19.
Gene ; 128(2): 307-8, 1993 Jun 30.
Article in English | MEDLINE | ID: mdl-8514199

ABSTRACT

Infection of Spodoptera frugiperda insect cells with a recombinant baculovirus expressing human cytosolic phospholipase A2 (cPLA2) resulted in the production of biologically active protein. The level of recombinant human cPLA2 production in infected insect cells was at least 50-fold higher than that observed in human monoblast U937 cells.


Subject(s)
Phospholipases A/genetics , Animals , Baculoviridae , Cytosol/enzymology , DNA, Recombinant , Humans , Moths , Phospholipases A/biosynthesis , Phospholipases A2 , Recombinant Fusion Proteins/biosynthesis , Recombinant Fusion Proteins/genetics
20.
J Biol Chem ; 266(34): 23204-14, 1991 Dec 05.
Article in English | MEDLINE | ID: mdl-1744118

ABSTRACT

Cyclophilin (CyP), a major cytosolic protein possessing peptidyl-prolyl cis-trans isomerase activity, has been implicated as the specific receptor of the immunosuppressive drug cyclosporin A (CsA). To identify other potential CsA receptors related to CyP, two human cDNA libraries were screened under low stringency conditions using human CyP cDNA (encoding hCyP1) as a probe. Two cDNAs were identified which encode distinct proteins related to human hCyP1. These two novel proteins, designated hCyP2 and hCyP3, share 65 and 76% amino acid sequence homology with hCyP1, respectively. Both hCyP2 and hCyP3 contain NH2-terminal hydrophobic extensions of 32 and 42 amino acids, respectively. Protein-specific antibodies revealed the predominant association of hCyP2 and hCyP3 with membranes and subcellular organelles, which suggests that the amino-terminal leader sequences of the two CyP isoforms may act as signal peptides. In contrast to the results with hCyP1, Southern blot analysis indicated that both hCyP2 and hCyP3 gene sequences are represented infrequently in the human genome. Northern and Western blot analysis showed that the distribution of mRNA and proteins of the three hCyPs in differing tissues and cell types was similar. Each hCyP protein was expressed in Escherichia coli, purified, and shown to be an active peptidyl-prolyl isomerase. Substrate specificity was examined with 11 synthetic peptides (Suc-Xaa-Yaa-Pro-Phe-4-nitroanilide), and inhibition of the peptidyl-prolyl isomerase activities associated with hCyP1, hCyP2, and hCyP3 was studied with CsA, MeAla6-CsA and MeBm2t1-CsA. From both equilibrium considerations and the results of kinetic characterizations it is proposed that of these three CyP proteins, hCyP1 is the most likely intracellular target for CsA.


Subject(s)
Amino Acid Isomerases/genetics , Carrier Proteins/genetics , Isoenzymes/genetics , Multigene Family , Amino Acid Isomerases/isolation & purification , Amino Acid Isomerases/metabolism , Amino Acid Sequence , Base Sequence , Blotting, Northern , Blotting, Southern , Carrier Proteins/isolation & purification , Carrier Proteins/metabolism , Cell Line , Cloning, Molecular , Cyclosporine/metabolism , DNA , Electrophoresis, Polyacrylamide Gel , Humans , Isoenzymes/isolation & purification , Isoenzymes/metabolism , Molecular Sequence Data , Organ Specificity/genetics , Peptidylprolyl Isomerase , Recombinant Proteins/isolation & purification , Recombinant Proteins/metabolism , Sequence Alignment
SELECTION OF CITATIONS
SEARCH DETAIL
...